#202 Dementia Part 2: Gray Matters Segment

Most clinicians see dementia medications on the med rec, but many of us aren’t sure how much they actually help . In this episode we break down donepezil, memantine, and the new anti-amyloid drugs, and when to stop them. • Do cholinesterase inhibitors really work? • What should clinicians know about lecanemab and donanemab before referring patients? • How much benefit should we expect and for how long? • When should you deprescribe dementia medications ? 🔹 Sponsor: Caraway’s cookware set is a favorite for a reason. For 10% off, go to Carawayhome.com/ CoreIM or use code CoreIM at checkout. 🔹 Transcript and Shownotes 02:27 | Deep Dive 1: How do we deliver the news of a diagnosis of dementia? 09:41 | Deep Dive 2: Prescribing medications for cognitive decline 29:30 | Deep Dive 3: Patient-centered management for a patient with cognitive decline 35:46 | Deep Dive 4: Planning for an uncertain future Tags: CoreIM, Internal Medicine, Medical Education, Cognitive Screening, primary care, nurse practitioner, physician assistant Find the best disability insurance for you: Our Sponsors: * Check out FIGS: * Click for 15% off Premium Starter Kit at Branch Basics: Advertising Inquiries: Privacy & Opt-Out:

You can listen to #202 Dementia Part 2: Gray Matters Segment online on Radio and Podcast. Open the player on this page to stream the available audio.

#202 Dementia Part 2: Gray Matters Segment is an episode from Core IM | Internal Medicine Podcast by Core IM Team.

This episode is 47:16 long.

This episode was published on Mar 12, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Core IM | Internal Medicine Podcast when more episodes are available from the podcast feed.